GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkmate Pharmaceuticals Inc (NAS:CMPI) » Definitions » Total Current Liabilities

Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Total Current Liabilities : $11.94 Mil (As of Mar. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Checkmate Pharmaceuticals Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Checkmate Pharmaceuticals's total current liabilities for the quarter that ended in Mar. 2022 was $11.94

Checkmate Pharmaceuticals Total Current Liabilities Historical Data

The historical data trend for Checkmate Pharmaceuticals's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Checkmate Pharmaceuticals Total Current Liabilities Chart

Checkmate Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Total Current Liabilities
3.32 5.63 7.88 9.38

Checkmate Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.31 6.70 7.81 9.38 11.94

Checkmate Pharmaceuticals Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Checkmate Pharmaceuticals's Total Current Liabilities for the fiscal year that ended in Dec. 2021 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=9.379+0
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=9.38

Checkmate Pharmaceuticals's Total Current Liabilities for the quarter that ended in Mar. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=11.942+0
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=11.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Checkmate Pharmaceuticals Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Checkmate Pharmaceuticals's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkmate Pharmaceuticals Inc (NAS:CMPI) » Definitions » Total Current Liabilities
Comparable Companies
VSTM OCUL PEPG EPIX AUTL COGT ENOB ALVR ADAP BLUE OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122
Traded in Other Exchanges
N/A
Address
245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Website
https://www.checkmatepharma.com
Checkmate Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing its proprietary technology to harness the power of the immune system to combat cancer.
Executives
Venbio Global Strategic Fund Ii L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Alan Bash director, officer: Chief Executive Officer C/O CHECKMATE PAHRMACEUTICALS, INC. 245 MAIN STREET 2ND FLOOR CAMBRIDGE MA 02142
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Jon Marc Wigginton director 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Joy Yan director 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Arthur M Krieg director, officer: Chief Scientific Officer C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Robert Dolski officer: Chief Financial Officer C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Barry Labinger director, officer: President and CEO C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Peter Colabuono director C/O DECHENG CAPITAL 3000 SAND HILL ROAD, BUILDING 2, STE 110 MENLO PARK CA 94025
Oren Isacoff director C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025
Karen Brennan officer: Chief Operating Officer C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Kleem Chaudhary officer: Chief Business Officer C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Venbio Global Strategic Gp Ii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Gp Ii, Ltd. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Nilesh Kumar director C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL A8 H4M 2X6

Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Headlines

From GuruFocus

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates TVTY, ACC, SWCH, CMPI

By PRNewswire PRNewswire • 05-17-2022

Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

By GuruFocusNews GuruFocusNews • 05-12-2022

SHAREHOLDER ALERT: Weiss Law Reminds FSI, NTUS, ACC, and CMPI Shareholders About Its Ongoing Investigations

By PRNewswire PRNewswire • 05-05-2022

University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

By GuruFocusNews GuruFocusNews • 06-25-2022

SHAREHOLDER ALERT: Weiss Law Reminds FSI, NTUS, ACC, and CMPI Shareholders About Its Ongoing Investigations

By PRNewswire PRNewswire • 05-16-2022

SHAREHOLDER ALERT: Weiss Law Reminds FSI, NTUS, ACC, and CMPI Shareholders About Its Ongoing Investigations

By PRNewswire PRNewswire • 05-26-2022

Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

By GuruFocusNews GuruFocusNews • 06-01-2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates PSB, FSI, TWTR

By PRNewswire PRNewswire • 04-26-2022

CHECKMATE PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of CMPI and Encourages Investors to Contact the Firm

By GuruFocusNews GuruFocusNews • 04-19-2022

SHAREHOLDER ALERT: Weiss Law Reminds FSI, NTUS, ACC, and CMPI Shareholders About Its Ongoing Investigations

By PRNewswire PRNewswire • 06-05-2022